Should I buy or sell Ligand Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks .

What is Ligand Pharmaceuticals' stock price target for 2024?

3 Wall Street research analysts have issued 12 month target prices for Ligand Pharmaceuticals' shares. Their LGND share price targets range from $95.00 to $144.00. On average, they anticipate the company's share price to reach $116.33 in the next year. This suggests a possible upside of 60.5% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts .

How have LGND shares performed in 2024?

Ligand Pharmaceuticals' stock was trading at $71.42 at the beginning of the year. Since then, LGND stock has increased by 1.5% and is now trading at $72.47. View the best growth stocks for 2024 here .

Are investors shorting Ligand Pharmaceuticals?

Ligand Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 672,100 shares, a decrease of 23.3% from the March 15th total of 876,300 shares. Based on an average daily volume of 162,300 shares, the days-to-cover ratio is currently 4.1 days. Currently, 4.1% of the shares of the stock are short sold. View Ligand Pharmaceuticals' Short Interest .

When is Ligand Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our LGND earnings forecast .

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported $0.79 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $0.55. The biotechnology company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $24.54 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 11.98% and a net margin of 37.80%.

What ETFs hold Ligand Pharmaceuticals' stock?

ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , iShares Genomics Immunology and Healthcare ETF (IDNA) , Virtus LifeSci Biotech Products ETF (BBP) , Invesco S&P SmallCap Health Care ETF (PSCH) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , Franklin Genomic Advancements ETF (HELX) and iShares U.S. Pharmaceuticals ETF (IHE) .

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY24 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of $4.25 to $4.75 for the period, compared to the consensus earnings per share estimate of $4.28. The company issued revenue guidance of $130 million to $142 million, compared to the consensus revenue estimate of $137.66 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com . John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ) , Micron Technology (MU) , NVIDIA (NVDA) , Alibaba Group (BABA) , Intel (INTC) , AbbVie (ABBV) , Netflix (NFLX) , Cisco Systems (CSCO) , Illumina (ILMN) and Gilead Sciences (GILD) .

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.48%), AMI Asset Management Corp (0.23%), BTC Capital Management Inc. (0.03%) and M&R Capital Management Inc. (0.01%). Insiders that own company stock include Andrew Reardon, John L Higgins , John W Kozarich, Matthew W Foehr , Octavio Espinoza, Stephen L Sabba and Todd C Davis. View institutional ownership trends .

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free LGND Stock Alerts

$72.47

-0.05 (-0.07%)

(As of 04/19/2024 ET)

Compare

Today's Range: $71.16
▼
$72.95
50-Day Range: $68.64
▼
$89.20
52-Week Range: $49.24
▼
$94.57

Volume: 137,196 shs
Average Volume: 144,024 shs
Market Capitalization: $1.28 billion

P/E Ratio: 26.35
Dividend Yield: N/A
Price Target: $116.33

Get Ligand Pharmaceuticals alerts:

Ligand Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 60.5% Upside
$116.33 Price Target
Short Interest: Healthy
4.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.57
Upright™ Environmental Score
News Sentiment: 0.84
Based on 4 Articles This Week
Insider Trading: Selling Shares
$153,034 Sold Last Quarter
Proj. Earnings Growth: 16.72%
From $3.41 to $3.98 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.92 out of 5 stars

Medical Sector

21st out of 911 stocks

Pharmaceutical Preparations Industry

7th out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
Ligand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ligand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.05% of the float of Ligand Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Ligand Pharmaceuticals has recently decreased by 23.30%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ligand Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ligand Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ligand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Ligand Pharmaceuticals is -1.57.

2.1

News and Social Media Coverage

News Sentiment
Ligand Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 5 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $153,034.00 in company stock.
Percentage Held by Insiders
10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Ligand Pharmaceuticals are expected to grow by 16.72% in the coming year, from $3.41 to $3.98 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ligand Pharmaceuticals is 26.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.18.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ligand Pharmaceuticals is 26.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 177.41.
Price to Book Value per Share Ratio
Ligand Pharmaceuticals has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Ligand Pharmaceuticals Stock (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

LGND Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LGND Stock News Headlines

April 17, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know

April 14, 2024 | americanbankingnews.com

Ligand Pharmaceuticals' (LGND) Buy Rating Reaffirmed at Benchmark

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | finance.yahoo.com

Can Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Performance Keep Up Given Its Mixed Bag Of Fundamentals?

April 8, 2024 | investorplace.com

7 Small-Cap Stocks for the Thinking Speculator

April 8, 2024 | businesswire.com

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

March 28, 2024 | finance.yahoo.com

Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?

March 27, 2024 | msn.com

Ligand Pharmaceuticals gains amid bullish investor pitch

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 16, 2024 | finance.yahoo.com

LGND Apr 2024 70.000 put

March 16, 2024 | finance.yahoo.com

LGND Apr 2024 110.000 call

March 6, 2024 | uk.finance.yahoo.com

Ligand Pharmaceuticals Incorporated (LGND)

March 5, 2024 | businesswire.com

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

March 4, 2024 | businesswire.com

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 3, 2024 | ca.finance.yahoo.com

LGND Aug 2024 110.000 call

March 3, 2024 | ca.finance.yahoo.com

LGND Apr 2024 90.000 call

February 28, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC)

February 28, 2024 | finance.yahoo.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

Ligand Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

February 27, 2024 | msn.com

Why Is Ligand Pharmaceuticals Stock Trading Higher Today?

February 27, 2024 | finance.yahoo.com

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024 | finance.yahoo.com

Ligand Pharmaceuticals Inc (LGND) Reports Solid Earnings Amidst Operational Transformation

February 27, 2024 | businesswire.com

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | benzinga.com

Ligand Pharmaceuticals's Earnings: A Preview

February 26, 2024 | msn.com

Ligand Pharmaceuticals Q4 2023 Earnings Preview

February 23, 2024 | finance.yahoo.com

LGND Mar 2024 65.000 put

February 22, 2024 | msn.com

Esai gets Japanese approval for epilepsy drug using Ligand technology

See More Headlines

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:LGND
CUSIP: 53220K50
CIK: 886163
Web: www.ligand.com
Phone: (858) 550-7500
Fax: 858-550-1826
Employees: 58
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $116.33
High Stock Price Target: $144.00
Low Stock Price Target: $95.00
Potential Upside/Downside: +60.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.75
Trailing P/E Ratio: 26.35
Forward P/E Ratio: 21.25
P/E Growth: N/A
Net Income: $52.15 million
Net Margins: 37.80%
Pretax Margin: 48.48%
Return on Equity: 11.98%
Return on Assets: 10.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.15
Quick Ratio: 12.72

Sales & Book Value

Annual Sales: $131.31 million
Price / Sales: 9.77
Cash Flow: $5.00 per share
Price / Cash Flow: 14.50
Book Value: $40.39 per share
Price / Book: 1.79

Miscellaneous

Outstanding Shares: 17,700,000
Free Float: 15,864,000
Market Cap: $1.28 billion
Optionable: Optionable
Beta: 1.01

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Todd C. Davis Ph.D. (Age 63)
CEO & Director
Comp: $743.49k
Mr. Matthew E. Korenberg (Age 49)
President & COO
Comp: $760.99k
Mr. Octavio Espinoza (Age 53)
Chief Financial Officer
Comp: $457.19k
Mr. Andrew T. Reardon J.D. (Age 49)
Chief Legal Officer & Secretary
Comp: $480.16k
Mr. Paul J. Hadden
Senior Vice President of Investments & Business Development
Simon Latimer
Head of Investor Relations
Mr. Todd Pettingill
Director of Corporate Development
Ms. Audrey Warfield-Graham
Chief People Officer
Dr. Keith Marschke
Senior Vice President of Biology & Scientific Affairs
Dr. Vincent D. Antle (Age 55)
Senior Vice President of Technical Operations & QA - Capitsol

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LGND Stock Analysis - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares.
View LGND analyst ratings or view top-rated stocks.
What is Ligand Pharmaceuticals' stock price target for 2024?: 3 Wall Street research analysts have issued 12 month target prices for Ligand Pharmaceuticals' shares. Their LGND share price targets range from $95.00 to $144.00. On average, they anticipate the company's share price to reach $116.33 in the next year. This suggests a possible upside of 60.5% from the stock's current price.
View analysts price targets for LGND or view top-rated stocks among Wall Street analysts.
How have LGND shares performed in 2024?: Ligand Pharmaceuticals' stock was trading at $71.42 at the beginning of the year. Since then, LGND stock has increased by 1.5% and is now trading at $72.47.
View the best growth stocks for 2024 here.
Are investors shorting Ligand Pharmaceuticals?: Ligand Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 672,100 shares, a decrease of 23.3% from the March 15th total of 876,300 shares. Based on an average daily volume of 162,300 shares, the days-to-cover ratio is currently 4.1 days. Currently, 4.1% of the shares of the stock are short sold.
View Ligand Pharmaceuticals' Short Interest.
When is Ligand Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LGND earnings forecast.
How were Ligand Pharmaceuticals' earnings last quarter?: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported $0.79 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $0.55. The biotechnology company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $24.54 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 11.98% and a net margin of 37.80%.

What ETFs hold Ligand Pharmaceuticals' stock?: ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Franklin Genomic Advancements ETF (HELX) and iShares U.S. Pharmaceuticals ETF (IHE).
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?: Ligand Pharmaceuticals issued an update on its FY24 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of $4.25 to $4.75 for the period, compared to the consensus earnings per share estimate of $4.28. The company issued revenue guidance of $130 million to $142 million, compared to the consensus revenue estimate of $137.66 million.
What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?: 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Ligand Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).
Who are Ligand Pharmaceuticals' major shareholders?: Ligand Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.48%), AMI Asset Management Corp (0.23%), BTC Capital Management Inc. (0.03%) and M&R Capital Management Inc. (0.01%). Insiders that own company stock include Andrew Reardon, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis.
View institutional ownership trends.
How do I buy shares of Ligand Pharmaceuticals?: Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LGND) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial